Simulations Plus Inc., a leading provider in the biopharma industry, has announced a $1 million equity investment in Nurocor, a technology company specializing in clinical development. The investment is part of Simulations Plus' Corporate Development Initiative, launched in 2024 to support early-stage tech companies and foster growth within the pharmaceutical sector. Nurocor, founded in 2017, offers a cloud-based software platform that enhances efficiency and automation in clinical trials, ultimately reducing development costs. This strategic investment aims to accelerate innovations in biopharma development, aligning with Simulations Plus' strategy to expand its market reach and deliver faster, cost-effective solutions to its clients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.